Department of Obstetrics and Gynecology

Research
Home > Research > Faculty Investigators > Frederick B. Stehman, MD

Frederick B. Stehman, MD

12950596654_sNCrW1.jpgFrederick B. Stehman, MD

The Clarence E. Ehrlich Professor, Emeritus
Department of Obstetrics and Gynecology

Clinical Section: Gynecologic Oncology

Fellowship: Gynecologic Oncology
University of California at Los Angeles

Residency: Obstetrics and Gynecology, 1975
Surgery, 1977
University of Kansas

MD: University of Michigan, 1972

Undergraduate: A.B., University of Michigan, 1968

E-mail: FStehman@iupui.edu

Address: Indiana Cancer Pavilion
535 Barnhill Drive
Indianapolis, IN 46202

Pub Med Search: http://www.ncbi.nlm.nih.gov/pubmed/?term=Stehman+FB

IU Research Connect: http://www.experts.scival/com/indiana/default.asp

Current Research Projects:

IU participates in the Gynecologic Oncology Group (GOG), is a non-profit international organization with the purpose of promoting excellence in the quality and integrity of clinical and basic scientific research in the field of Gynecologic malignancies. The Group is committed to maintaining the highest standards in clinical trials development, execution, analysis and distribution of results.

The following are the current projects/protocols:

  1. Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?
  2. A Randomized Trial of Pelvic Irradiation with or Without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
  3. Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy
  4. A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120112) in Patients with Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer.
  5. A Phase II Trial of DCTD-Sponsored Dastinib (NSC #7532517 IND #120636) in Recurrent/Persistent Ovary, Fallopian Tube, Primary Peritoneal, and Endometrial Clear Cell Carcinoma Characterized for the Retention or Loss of BAF250a Expression
  6. A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
  7. A phase III randomized controlled clinical trial of carboplatin and paclitaxel alone or in combination with bevacizumab (NSC #704865, IND #7921) followed by bevacizumab and secondary cytoreductive surgery in platinum-sensitive, recurrent ovarian, peritoneal primary and fallopian tube cancer, NCI-Supplied agents: BEVACIZUMAB (NSC #704865, IND #7921.
  8. A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
  9. A Phase II Trial Evaluating Cisplatin (NSC #119875) and Gemcitabine (NSC #613327) Concurrent with Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Vulva

Indiana University School of Medicine
Department of Obstetrics and Gynecology
550 University Blvd
Indianapolis, IN 46202


obgyniu@iupui.edu

A gift to the department of Obstetrics and Gynecology can be made online through our Gift Development Department or through the mail with a linkedĀ PDF Form.

 

Thank you for making a difference!

For information about the various ways to give or on unique procedures we perform, please contact us at 317-944-8609.